Interestingly, despite both AIT and omalizumab have confirmed a clinical benefit in a variety of IgE-mediated allergic diseases -i.e., allergic rhinitis and/or asthma and chronic spontaneous urticaria- their role in AD is still controversial (30–32). Here, IGHE is linked to asthma.